BACKGROUND: The frequent provocation of ventricular tachycardia by stress or catecholamines and the efficacy of antiarrhythmic drugs with antiadrenergic properties suggest an involvement of the cardiac adrenergic system in arrhythmogenesis in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Previous studies demonstrated abnormalities of the presynaptic uptake-1 assessed by (123)I-MIBG-single-photon emission computed tomography. METHODS AND RESULTS: This study investigated neuronal reuptake of norepinephrine (uptake-1) and beta-adrenergic receptor density in 8 patients with ARVC and 29 age-matched control subjects. All subjects underwent positron emission tomography with the volume of distribution (V(d)) of [(11)C]hydroxyephedrine ((11)C-HED) used to assess presynaptic norepinephrine reuptake, the maximum binding capacity (B(max)) of [(11)C]CGP-12177 ((11)C-CGP-12177) to assess postsynaptic beta-adrenergic receptor density, and [(15)O]H(2)O for quantification of myocardial blood flow. Patients with ARVC demonstrated a highly significant global reduction in postsynaptic beta-adrenergic receptor density compared with that in control subjects (B(max) of (11)C-CGP-12177: 5.9+/-1.3 vs 10.2+/-2.9 pmol/g tissue, P<0.0007), whereas the presynaptic uptake-1 tended toward reduction only (V(d) of (11)C-HED: 59.1+/-25.2 vs 71.0+/-18.8 mL/g tissue, NS). There were no differences in myocardial blood flow between the groups, and plasma norepinephrine was within normal limits in patients and control subjects. CONCLUSIONS: The findings demonstrate a significant reduction of myocardial beta-adrenergic receptor density in patients with ARVC. This may result from a secondary downregulation after increased local synaptic norepinephrine levels caused by increased firing rates of the efferent neurons or as the result of impaired presynaptic catecholamine reuptake. These findings give new insights into the pathophysiology of arrhythmogenesis in ARVC, with potential impact on diagnostic evaluation and therapeutic management.
BACKGROUND: The frequent provocation of ventricular tachycardia by stress or catecholamines and the efficacy of antiarrhythmic drugs with antiadrenergic properties suggest an involvement of the cardiac adrenergic system in arrhythmogenesis in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Previous studies demonstrated abnormalities of the presynaptic uptake-1 assessed by (123)I-MIBG-single-photon emission computed tomography. METHODS AND RESULTS: This study investigated neuronal reuptake of norepinephrine (uptake-1) and beta-adrenergic receptor density in 8 patients with ARVC and 29 age-matched control subjects. All subjects underwent positron emission tomography with the volume of distribution (V(d)) of [(11)C]hydroxyephedrine ((11)C-HED) used to assess presynaptic norepinephrine reuptake, the maximum binding capacity (B(max)) of [(11)C]CGP-12177 ((11)C-CGP-12177) to assess postsynaptic beta-adrenergic receptor density, and [(15)O]H(2)O for quantification of myocardial blood flow. Patients with ARVC demonstrated a highly significant global reduction in postsynaptic beta-adrenergic receptor density compared with that in control subjects (B(max) of (11)C-CGP-12177: 5.9+/-1.3 vs 10.2+/-2.9 pmol/g tissue, P<0.0007), whereas the presynaptic uptake-1 tended toward reduction only (V(d) of (11)C-HED: 59.1+/-25.2 vs 71.0+/-18.8 mL/g tissue, NS). There were no differences in myocardial blood flow between the groups, and plasma norepinephrine was within normal limits in patients and control subjects. CONCLUSIONS: The findings demonstrate a significant reduction of myocardial beta-adrenergic receptor density in patients with ARVC. This may result from a secondary downregulation after increased local synaptic norepinephrine levels caused by increased firing rates of the efferent neurons or as the result of impaired presynaptic catecholamine reuptake. These findings give new insights into the pathophysiology of arrhythmogenesis in ARVC, with potential impact on diagnostic evaluation and therapeutic management.
Authors: Marilyn P Law; Stefan Wagner; Klaus Kopka; Christiane Renner; Victor W Pike; Otmar Schober; Michael Schäfers Journal: Nucl Med Biol Date: 2010-05 Impact factor: 2.408
Authors: Grace P Chen; Ramin Tabibiazar; Kelley R Branch; Jeanne M Link; James H Caldwell Journal: J Nucl Cardiol Date: 2005 Nov-Dec Impact factor: 5.952
Authors: Lars Stegger; Klaus Schäfers; Klaus Kopka; Stefan Wagner; Sven Hermann; Peter Kies; Marilyn Law; Otmar Schober; Michael Schäfers Journal: Eur Radiol Date: 2007-01-06 Impact factor: 5.315
Authors: Maureen M Henneman; Frank M Bengel; Ernst E van der Wall; Juhani Knuuti; Jeroen J Bax Journal: J Nucl Cardiol Date: 2008-04-16 Impact factor: 5.952
Authors: Larissa Fabritz; Dierk Damke; Markus Emmerich; Susann G Kaufmann; Kathrin Theis; Andreas Blana; Lisa Fortmüller; Sandra Laakmann; Sven Hermann; Elena Aleynichenko; Johannes Steinfurt; Daniela Volkery; Burkhard Riemann; Uwe Kirchhefer; Michael R Franz; Günter Breithardt; Edward Carmeliet; Michael Schäfers; Sebastian K G Maier; Peter Carmeliet; Paulus Kirchhof Journal: Cardiovasc Res Date: 2010-01-28 Impact factor: 10.787
Authors: Daniel Juneau; Fernanda Erthal; Benjamin J W Chow; Calum Redpath; Terrence D Ruddy; Juhani Knuuti; Rob S Beanlands Journal: J Nucl Cardiol Date: 2016-07-28 Impact factor: 5.952